The U.S. Food and Drug Administration has approved the use of its early access pathway to allow patients to receive Revolution Medicines' investigational pill daraxonrasib before formal regulatory approval, the company announced on Friday. The authorization applies to patients with metastatic pancreatic ductal adenocarcinoma, a form of pancreatic cancer that has spread beyond the pancreas, who have already undergone prior therapies.
FDA early access programs permit people with serious or life-threatening conditions to obtain experimental treatments outside of clinical trials prior to a drug receiving full approval. In this instance, daraxonrasib is being made available through that mechanism while its formal regulatory review continues.
Revolution Medicines previously disclosed late-stage trial results in April indicating daraxonrasib doubled the survival period for patients with pancreatic cancer compared with chemotherapy in the trial referenced by the company. That clinical readout coincided with a notable rise in the companys share price, according to the companys statement.
Daraxonrasib is not limited to the pancreatic cancer program; it is also under evaluation in other late-stage studies, including trials for non-small cell lung cancer. Additionally, the medicine has been granted a priority review voucher by the FDA, a mechanism intended to accelerate the development and review process for therapies addressing unmet medical needs.
Revolution Medicines said it is preparing to open the early access program in the United States as quickly as possible while focusing on safe and equitable patient access. The company reiterated that, under FDA rules, individual patients and caregivers cannot apply directly to the company for participation. Rather, requests for early access must be submitted by a licensed treating physician on the patients behalf.
Context and implications
The FDA authorization permits the investigational pill to reach patients outside clinical trials ahead of full approval, potentially expanding treatment options for a population with limited alternatives. The company's public comments emphasize both speed of implementation and adherence to safeguards intended to ensure fairness and safety in access.
How broadly and quickly the program will be implemented depends on operational steps the company takes to enroll eligible patients and on physicians initiating requests on behalf of their patients.